132 studies found for:    "AL amyloidosis"
Show Display Options
Rank Status Study
21 Completed Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis
Condition: Amyloidosis
Interventions: Drug: Bortezomib;   Drug: dexamethasone;   Biological: filgrastim;   Procedure: autologous hematopoietic stem cell transplantation (ASCT);   Drug: Melphalan
22 Suspended Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis
Condition: Primary Systemic Amyloidosis
Intervention: Drug: Enbrel
23 Terminated Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Conditions: Light Chain Deposition Disease;   Primary Systemic Amyloidosis
Interventions: Drug: melphalan;   Drug: dexamethasone;   Drug: bortezomib
24 Recruiting A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
Conditions: Amyloidosis;   Systemic Light Chain Amyloidosis
Interventions: Drug: Carfilzomib;   Drug: Dexamethasone
25 Active, not recruiting S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
Conditions: Multiple Myeloma;   Plasma Cell Myeloma
Interventions: Biological: filgrastim;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: melphalan;   Drug: thalidomide;   Procedure: peripheral blood stem cell transplantation
26 Recruiting Phase I, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Condition: Primary Amyloidosis
Intervention: Drug: NEOD001
27 Completed S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma
Interventions: Biological: recombinant interferon alfa;   Drug: dexamethasone
28 Completed CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone;   Drug: lenalidomide
29 Active, not recruiting Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone;   Drug: lenalidomide;   Drug: melphalan
30 Active, not recruiting Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Drug: bortezomib;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation
31 Completed A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis
Conditions: Leukemia;   Amyloidosis
Interventions: Drug: Lenalidomide;   Drug: Melphalan;   Drug: Dexamethasone
32 Active, not recruiting Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
Conditions: Multiple Myeloma;   Primary Amyloidosis
Interventions: Drug: Melphalan;   Procedure: Stem Cell Infusion;   Behavioral: Questionnaires;   Drug: Granulocyte-colony stimulating factor (G-CSF);   Procedure: Apheresis
33 Completed Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis
Condition: Amyloidosis
Interventions: Drug: cyclophosphamide;   Drug: lenalidomide;   Drug: dexamethasone
34 Recruiting Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
Conditions: Light Chain Deposition Disease (LCDD or MIDD);   Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD);   Monoclonal Immunoglobulin Deposition Disease (MIDD);   Amyloidosis
Intervention: Drug: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
35 Completed
Has Results
Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: lenalidomide
36 Completed Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Drug: dexamethasone;   Drug: melphalan;   Drug: thalidomide
37 Completed High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Drug: melphalan;   Procedure: bone marrow ablation with stem cell support;   Procedure: peripheral blood stem cell transplantation
38 Completed Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Biological: recombinant interferon alfa;   Biological: sargramostim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: melphalan;   Procedure: autologous bone marrow transplantation;   Procedure: bone marrow ablation with stem cell support;   Procedure: peripheral blood stem cell transplantation
39 Completed 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Intervention: Drug: 4'-iodo-4'-deoxydoxorubicin
40 Terminated Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
Conditions: Drug/Agent Toxicity by Tissue/Organ;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Drug: amifostine trihydrate;   Drug: melphalan;   Procedure: bone marrow ablation with stem cell support;   Procedure: peripheral blood stem cell transplantation

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years